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Abstract: Respiratory syncytial virus (RSV) is a significant cause of morbidity in 
high-risk infants. Palivizumab is proven to prevent serious RSV disease, but compliance with 
prophylaxis (monthly doses during the RSV season) is essential to ensure protection. We invited 
453 pediatricians to participate in a survey to identify their perspectives of barriers to compliance 
and interventions to improve compliance with palivizumab prophylaxis schedules. One hundred 
physicians from five continents completed the survey, identifying caregiver inconvenience, 
distance to clinic, cost of prophylaxis, and lack of understanding of the severity of RSV as 
the most common reasons for noncompliance. They recommended provision of educational 
materials about RSV, reminders from hospital or clinic, and administration of prophylaxis at 
home to increase compliance. Globally, physicians recognize several obstacles to prophylaxis 
compliance. This survey suggests that focused proactive interventions such as empowering 
caregivers with educational materials and reducing caregiver inconvenience may be instrumental 
to increase compliance.
Keywords: medication adherence, respiratory syncytial virus infections, infant, premature, 
immunization, passive
Adherence to health care interventions is an important part of enhancing health. 
Nonadherence to intervention, be it pharmaceutical or surgical treatment, physical 
therapy, dietary changes, lifestyle changes, screening procedures, vaccinations, or any 
other regimen, has significant consequences for patients in terms of outcome and quality 
of life, as well as a significant cost and resource burden on the health care system.
The World Health Organization (WHO), in its report on adherence to medica-
tions, defined adherence to long-term therapy as: “The extent to which a person’s 
behaviour ... corresponds with agreed recommendations from a health care provider.”1 
The definition recognizes the partnership between patients and providers in making 
health care choices, in which the patient is an active participant in decisions and not 
a passive recipient of instructions from the physician or other health care provider. 
While this definition was adopted in the context of treatment for chronic conditions, 
it is also applicable to surveillance activities, such as routine screening procedures, 
or preventive measures, such as vaccination schedules.
The WHO report and much of the literature describe adherence related to chronic 
disease, but nonadherence to disease prophylaxis regimens is also of concern. The 
economic burden caused by nonadherence to prophylaxis against many preventable 
infectious diseases can be estimated, but it is less straightforward to estimate costs Patient Preference and Adherence 2009:3 196
Anderson et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
associated with partial adherence, for example to some but 
not all vaccines or to some but not all doses of an individual 
vaccine.
Respiratory syncytial virus (RSV) infection is the 
leading cause of lower respiratory tract infection (LRTI) 
in infants.2 RSV is a seasonal virus in most regions of the 
world. Epidemics lasting 4–6 months occur during the 
winter season in temperate climates, with peak infection 
periods in December and January in the northern United 
States, Canada, and much of northern Europe.3 By the 
age of two years, nearly all children have been infected.2 
Generally, RSV infection results in an upper respiratory 
tract infection; however, 25% to 40% of  infected children 
develop a mild-to-moderate LRTI, and about 1% of previously 
healthy infected children require hospitalization. Risk factors 
contributing to serious RSV disease and hospitalization 
include chronic lung disease, congenital heart disease, and 
premature birth (35 weeks gestational age).3,4 Greenough5 
and Sampalis6 demonstrated that RSV hospitalization is 
associated with greater utilization of health care resources 
in infants 35 weeks of gestation. RSV-LRTI and associ-
ated hospitalizations pose a significant burden of illness to 
patients and their families and have an economic impact on 
the health care system.7 Prevention of RSV-LRTI may thus 
reduce this burden to families and society in general.
Because no licensed vaccines are currently available 
to prevent RSV infection, passive immunoprophylaxis 
with anti-RSV IgG antibody is the only option for 
preventing RSV disease in high-risk children. Two 
passive immunoprophylaxis agents are approved for the 
prevention of RSV infection. Palivizumab (marketed in the 
US by MedImmune, LLC, Gaithersburg, MD; marketed 
outside the US by Abbott, Abbott Park, IL) is a humanized 
immunoglobulin G (IgG) monoclonal antibody approved 
for use in infants at high risk for severe RSV disease, and is 
administered monthly by intramuscular injection throughout 
the RSV season. Intravenous RSV immunoglobulin (RSV-Ig) 
is prepared from pooled human blood, and is administered 
monthly by intravenous (IV) infusion during the RSV 
season. Guideline recommendations for RSV prophylaxis 
in high-risk infants have been published by the American 
Academy of Pediatrics,8 the Canadian Paediatric Society,9 
and other organizations dedicated to children’s health and 
disease prevention. Though both palivizumab and RSV-Ig are 
included in guideline recommendations,8,9 palivizumab is the 
preferred agent for RSV prophylaxis; not only is it effective, 
it is also convenient to administer, leading to significantly 
reduced time costs for patients’ families.10 Intramuscular 
injection is completed in a matter of minutes, compared with 
several hours required to complete IV infusion. In addition, 
IM injection is a simple procedure that can be performed by 
medical office staff, whereas IV infusion requires specialized 
training and equipment.
Palivizumab is not a vaccine. It provides passive 
immunization rather than eliciting an active immune response 
against RSV,4 and must be administered monthly during the 
RSV season in order to be effective. Palivizumab prophylaxis 
depends upon full compliance with the monthly dosing 
schedule. However, full compliance rates vary in different 
regions studied. In developed countries, rates between 36% 
and 98% have been reported,11–13 with differences depending 
not only on the region studied but also on where the doses 
are delivered (eg, central hospital, pediatrician’s office, or 
at a patient’s home).
As suggested by the widely varying rates reported, there 
are many barriers to full compliance with palivizumab 
prophylaxis. For example, Langkamp14 surveyed parents at 
a single center in the United States to identify barriers to full 
compliance and discovered that a key factor in compliance 
was parental belief in the benefit of palivizumab. Difficulty 
in transportation to the hospital to receive injections also was 
identified as a compliance barrier in that survey. Though not 
a significant factor in the Langkamp report, many parents 
were concerned about out-of-pocket costs of the drug and 
other indirect costs (eg, time spent negotiating with insurers). 
Bracht and colleagues11 established an RSV prevention 
program at three tertiary centers and the surrounding areas 
in Canada. Education of parents about risks of RSV disease 
and benefits of prophylaxis with palivizumab were key com-
ponents of the program, which achieved 98% compliance. 
Cost of the treatment was not a factor for this Canadian 
population, but the researchers identified language barriers 
and educational limitations in some families as obstacles to 
the full understanding of the instructional materials provided. 
Similarly, Pignotti15 identified language barriers which 
caused difficulty in communicating the severity of RSV and 
the proposed prophylactic schedule as being a key component 
of nonadherence to the full palivizumab dosing schedule in 
Italy. Singleton and colleagues16 reported that transportation 
delays from adverse weather conditions contribute to low 
compliance with recommended palivizumab administration 
in an Alaskan Native population. Compliance increased 
when palivizumab was delivered by a local trained health 
aide.16 Thus, previous work has revealed that a lack of 
parental understanding of RSV disease and prevention, 
communication obstacles, and transportation difficulties Patient Preference and Adherence 2009:3 197
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are important barriers to achieving full compliance with 
palivizumab prophylaxis.
We surveyed physicians to discover if their perceptions 
of barriers to full compliance with palivizumab prophylaxis 
matched those reported by patients’ families and in the 
literature. Pediatricians from countries in which palivizumab 
is approved for use were identified by Abbott medical 
directors and staff and invited by electronic mail to participate 
anonymously in an internet-based survey (http://www.
markettools.com/). Physicians attending an invitational global 
medical conference were invited to participate in the survey 
at on-site computer terminals. There was no duplication of 
invitations; physicians who attended the conference were 
not contacted by electronic mail to complete the survey. 
In all, 453 physicians were invited to respond to the survey 
questions. Some invited physicians prescribed palivizumab 
and some did not. The survey was provided in English and 
contained 29 questions to assess physician practice habits, 
perceptions of obstacles to compliance, and measures to 
enhance compliance with palivizumab prophylaxis (Table 1). 
One hundred physicians (response rate = 22%) completed 
the survey from Europe (n = 60), Asia (n = 15), North 
America (n = 13; Canada and Mexico only), South America 
(n = 7), and Africa (n = 5). Information about the responding 
physicians was based on their answers to survey questions. 
No information about nonresponders was collected.
The physicians responding to our survey identified 
inconvenience to parents and distance to the clinic, cost of 
palivizumab, and a lack of understanding of the threat of RSV 
as the primary barriers to adherence to the full dosing schedule 
(Figure 1). The most frequent barriers identified differed 
when the responses were stratified by region. For example, 
European physicians (n = 60) believed that inconvenience and 
distance to the clinic were the most important barriers to full 
compliance, whereas cost of prophylaxis was less important. 
By contrast, non-European physicians (n = 40) ranked cost 
as the primary barrier to full compliance with palivizumab 
prophylaxis, though inconvenience to caregivers was also 
thought to be important. Our survey asked physicians to 
speculate about the reasons their patients’ parents might be 
noncompliant with palivizumab dosing schedules, in contrast 
to other surveys in which parents were asked directly. It is 
interesting that the physicians in our survey identified barriers 
to adherence similar to those that have been reported from 
the perspectives of patients’ parents.
In our survey, physicians recommended additional 
educational materials and education of patients’ families about 
the threat from severe RSV disease, frequent reminders from 
the hospital, and administration of palivizumab in patients’ 
homes as key drivers of full compliance (Figure 2). The same 
drivers were identified when the responses were stratified 
by region (Europe versus non-Europe). Thus, our survey 
results emphasize the universal importance of educating 
families about RSV disease and palivizumab prophylaxis. 
In addition, the results support home administration of 
palivizumab as a driver for full compliance with the monthly 
dosing schedule, in agreement with previous work that has 
demonstrated higher compliance rates with home or local 
administration.12,16
Of the physicians responding to our survey, 68% believe 
that their patients’ parents think that palivizumab is a 
vaccine. In fact, 38% of the responding physicians believe 
that palivizumab is a vaccine. Thus, our survey identified a 
need for further education not only of patients’ families, but 
also in some cases of physicians themselves. Unlike most 
vaccines, palivizumab has a strict dosing schedule that must 
be followed to achieve efficacy throughout the RSV season. 
Equating palivizumab to a vaccine may cause caregivers or 
even physicians to falsely believe that a single injection will 
protect at-risk children. In our survey, 86% of the respondents 
provide information to their patients’ caregivers about RSV 
and prophylaxis. Physicians need to be fully educated about 
the action of palivizumab and the necessity of multiple doses 
on a strict schedule in order to effectively communicate the 
importance of adherence to their patients’ families.
Though the survey invited a large number of physicians 
to participate, the results are limited by bias in the selection 
process and the low rate of  response. Invitations to participate 
were not random, because contact information for a random 
sample of pediatricians in each country was unavailable. 
In addition, responders were more likely to be fluent in 
English than nonresponders, since the survey was provided 
in English. On the other hand, physicians practicing in devel-
oped as well as developing countries participated in the survey, 
leading to a broad spectrum of responses. Furthermore, the 
anonymity of the survey may have encouraged responders to 
answer the questions candidly, contributing some strength to 
the results. Indeed, the barriers to compliance and the recom-
mendations to increase compliance identified in this survey are 
similar to those previously reported in the literature, suggesting 
that the results may be generally applicable in a larger and 
more randomly selected population of pediatricians.
Infants are a special subpopulation in whom compliance 
to any medical regimen is dependent on parental decisions. 
Serious RSV disease resulting in hospitalization places 
a burden on families and on the health care system. Patient Preference and Adherence 2009:3 198
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Table 1 Survey questions
Number Question Answers/Options
1 Please select the country in which you currently practice. Drop-down list
2 Please select your specialty: –   Pediatrics
–   GP
–   Family medicine
–   Internal medicine
–   Combined internal 
medicine/Pediatrics
–   Surgery
–   Other, please specify
3 Please select your subspecialty: –   Neonatology
–   Pediatrics
–   Pulmonology
–   Cardiology
–   Infectious disease
–   Neurology
–   Immunology/Allergy
–   Intensive care
–   Other, please specify
4 How many years have you been a practicing physician? –   5
–   5–10
–   11–20
–   21–30
–   31–40
–   41
5 Please indicate your type of practice (Select all that apply): –   Academic
–   Private
–   Government
–   Other, please specify
6 What are the main sources of continuing education in your country? Please 
select all that apply.
–   University
–   Journals
–   Medical representatives
–     Medical or scientific 
memberships
–     Attendance at congresses 
or conferences
–   Other, please specify
7 Please indicate the level of your patients’ parents/caregivers education  
(in percent with total equaling 100%. If not known, please leave blank):
–   Highly educated (university)
–     Some education (primary 
and secondary)
–   No formal education
8 How do your patients pay you? Select all that apply. –   Self-pay
–   Government sponsored
–   Private insurance
–   Other, please specify
9 What percent of your patient population is born:
–   35 weeks gestational age?
–   With hemodynamically significant congenital heart disease?
Respondent fill-in
The following four (4) questions will refer to specific patient types. For simplification purposes, they will be coded as shown 
below:
    29 wGA, no BPD: 29 weeks gestational age without bronchopulmonary dysplasia (BPD) or chronic lung disease (CLD)
     29–32 wGA, no BPD: 29–32 weeks gestational age without BPD/CLD
     33–35 wGA, no BPD: 33–35 weeks gestational age without BPD/CLD
     BPD/CLD: diagnosed with BPD/CLD
     CHD: diagnosed with congenital heart disease (CHD)
(Continued)Patient Preference and Adherence 2009:3 199
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Table 1 (Continued)
Number Question Answers/Options
10 Which of the following patient types do you see/treat in your practice? Select 
all that apply
–   29 wGA, no BPD
–   29–32 wGA, no BPD
–   33–35 wGA, no BPD
–   BPD/CLD
–   CHD
–   None of the above
11 Please indicate your satisfaction with the literature supporting the use of 
palivizumab/Synagis® in the following high-risk groups.
–   29 wGA, no BPD:
–   29–32 wGA, no BPD:
–   33–35 wGA, no BPD:
–   BPD/CLD:
–   CHD:
Respondent fill-in using  
1–5 scale (1 = extremely 
satisfied – 5 = extremely 
dissatisfied)
12 In what percent of patients do you recommend palivizumab/Synagis® 
prophylaxis:
–   29 wGA, no BPD:
–   29–32 wGA, no BPD:
–   33–35 wGA, no BPD:
–   BPD/CLD:
–   CHD:
Respondent fill-in
Palivizumab/Synagis® is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused 
by respiratory syncytial virus (RSV) in children at high risk for RSV disease:
    •  Children born at 35 weeks of gestation or less and less than six months of age at the onset of the RSV season
    •  Children aged less than two years and requiring treatment for bronchopulmonary dysplasia within the last six months
    •  Children aged less than two years and with hemodynamically significant congenital heart disease
13 Have you ever NOT recommended palivizumab for a patient who met 
indications in the following patient groups?
–   29 wGA, no BPD
–   29–32 wGA, no BPD
–   33–35 wGA, no BPD
–   BPD/CLD
–   CHD
–   Other, please specify
Yes/No
14 Please select the top three (3) reasons why you would NOT recommend 
palivizumab/Synagis® for your indicated patients.
–   Lack of reimbursement
–   Lack of data to support use
–   Safety
–   Cost of palivizumab
–   Inconvenience for the 
patient/family
–     Inconvenience for the 
medical staff/nursing staff
–   Other, please specify
15 Are parents/caregivers of patients provided with information on the risks of 
severe RSV and palivizumab prophylaxis?
Yes/No
16 Please indicate in which format the information is provided. Select all that apply. –   Written (text only)
–   Pictures/diagrams (visuals 
with text)
–   Verbal
–   Other, please specify
17 Who is primarily responsible for providing the information to the patient’s 
parent/caregiver?
–   MD
–   Resident or fellow
–   Nurse
–   Office staff
–   Other, please specify
(Continued)Patient Preference and Adherence 2009:3 200
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Table 1 (Continued)
Number Question Answers/Options
18 Is written information provided in the parent/caregiver’s native language? Yes/No
19 For those who are not fluent in the local language, is an interpreter used? Yes/No
20 Are parents/caregivers requested to repeat the information provided to them 
in order to validate the teaching message?
Yes/No
21 When is RSV generally first discussed with your patients’ parents/caregivers? –     Prior to primary  
hospital discharge  
(ie, birth hospitalization)
–   After primary hospital 
discharge
–   During hospital  
re-admission
–   Never
–   Other, please specify
22 In patient populations where the parent/caregiver refuses initiation of 
prophylaxis, what do you believe are the top three (3) factors that  
contribute to a parent/caregiver’s refusal?
–   Inconvenience
–   Cost
–     Perceived lack of benefit 
from palivizumab/Synagis®
–     Incomplete knowledge of 
the threat from RSV
–     Palivizumab/Synagis® 
perceived as unsafe
–     Parent/caregiver’s belief 
that RSV exposure can be 
limited
–   Personal “antivaccine” 
beliefs
–   Cultural beliefs
–   Religious beliefs
–   Other, please specify
23 What do you believe are the top three (3) factors that contribute most to 
noncompliance with palivizumab/Synagis® recommendations? (Noncompliance 
is defined as infants who have therapy initiated, but do not receive all recom-
mended doses.)
–   Inconvenience to parents/
caregivers
–   Distance to clinic
–   Parent/caregiver time 
off work
–   Cost of product
–   Issues related to other 
children
–   Fear of injections
–   Lack of availability of 
palivizumab
–     Lack of perceived benefit of 
palivizumab by the parent/
caregiver
–     Perception by parent/
caregiver that the product 
is unsafe
–   Adverse reactions 
from palivizumab
–     Adverse reactions from 
other medications 
or vaccines
–     Lack of understanding 
regarding threat of RSV
–   Other, please specify
(Continued)Patient Preference and Adherence 2009:3 201
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Table 1 (Continued)
Number Question Answers/Options
24 What do you believe are the top three (3) factors that contribute most to full 
compliance with palivizumab/Synagis® recommendations? (Full compliance is 
defined as patients receiving all recommended doses.)
–     Educational materials 
regarding threat of RSV
–   RSV illness in a 
previous child
–   Recommendations from 
physician for palivizumab
–   Administration of 
palivizumab in a previous 
child
–   Coordination of palivizumab 
doses with other medical or 
vaccination visits
–   Prearranged transpor-
tation to palivizumab 
administration visits
–   Participation in parent or 
advocacy groups
–   Reminders of the 
palivizumab administra-
tion visit from the hospital 
or clinic
–   Administration of 
palivizumab in home
–   Home educational and 
hospital follow-up visits 
from nurses
–   Home educational and 
hospital follow-up visits 
from physicians
–   Other, please specify
25 In order to increase compliance, what are the top three (3) interventions you 
would recommend?
–   Additional educational 
materials
–   Satellite clinics
–   Frequent reminders from 
the hospital
–   Addition of home visits
–     Home administration of 
palivizumab prophylaxis
–   Education of patient’s family
–   Reimbursement
–     Transportation to the 
palivizumab dosing visits
–   Other, please specify
26 Considering your country’s routine immunization schedule, what % of children 
in your practice receive all recommended doses of immunizations?
–   0%–25%
–   26%–50%
–   51%–75%
–   76%–100%
–   My country does not have 
a routine immunization 
schedule
27 Do you view palivizumab/Synagis® as an equivalent to a vaccine? Yes/No
28 In your opinion, is palivizumab considered by the parents/caregivers of your 
patients to be equivalent to a vaccine?
Yes/No
29 If you do NOT intend to recommend palivizumab to a patient who meets the 
indications for prophylaxis, would you provide information about RSV to the 
parents/caregivers?
Yes/NoPatient Preference and Adherence 2009:3 202
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Inconvenience to parents/caregivers
Distance to clinic
Cost of product
Lack of understanding regarding threat of respiratory syncytial virus
Lack of perceived benefit of palivizumab by the parent/caregiver
Fear of injections
Parent/caregiver time off work
Lack of availability of palivizumab
Adverse reactions from other medications or vaccines
Issues related to other children
Adverse reactions from palivizumab
Perception by parent/caregiver that the product is unsafe
Other
41
36
34
30
24
24
22
10
9
9
4
4
2
Figure 1 Barriers to full compliance. Physicians were asked what they believed to be the top three factors that contribute most to noncompliance with recommended 
palivizumab dosing schedules.
2
13
18
23
30
38
49
51
58
Other
Transportation to the palivizumab dosing visits
Addition of home visits
Satellite clinics
Reimbursement
Home administration of palivizumab prophylaxis
Education of patient's family
Frequent reminders from the hospital
Additional educational materials
Figure 2 Recommended interventions. Physicians were asked to choose the top three interventions they would recommend to increase full compliance with palivizumab 
prophylaxis.Patient Preference and Adherence 2009:3
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Palivizumab prophylaxis has been shown to reduce the 
incidence of RSV-LRTI and hospitalization in at-risk 
infants,4,17 but effective prophylaxis requires full compli-
ance with the monthly dosing schedule. While several 
approaches to increasing full compliance with RSV 
prophylaxis may be beneficial, including cost reductions 
(in some areas of the world), frequent reminders, home or 
local administration, and assistance with transportation to 
clinics, it is critically important that parents of children at 
high risk for severe RSV disease be empowered with clear 
information about the threat from RSV and the benefits of 
palivizumab prophylaxis to enable them to make informed 
choices. Physicians and other health professionals are 
primary sources of information for patients or their 
caregivers, and thus play a key role in guiding families 
in their choices about RSV prophylaxis. The physicians 
we surveyed recognized both the importance of educating 
families about RSV and prophylaxis, and their own roles 
in providing this information.
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